Abstract
Findings from previous published studies regarding the association of the XRCC3 Thr241Met polymorphism with glioma susceptibility have often been conflicting. Therefore, a meta-analysis including all available publications was carried out to make a more precise estimation of the potential relationship. By searching the electronic databases of Pubmed and Embase (up to April 1st, 2013), a total of nine case-control studies with 3,752 cases and 4,849 controls could be identified for inclusion in the current meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of the association. This meta-analysis showed the XRCC3 Thr241Met polymorphism to be significantly associated with decreased glioma risk in the allelic model (Met allele vs. Thr allele: OR= 0.708, 95%CI= 0.631-0.795). Moreover, we also observed a statistically significant association between the XRCC3 Thr241Met polymorphism and reduced glioma risk in analyses stratified by ethnicity (Asian) and source of controls (hospital based) in the allelic model. Current evidence suggests that the XRCC3 Thr241Met polymorphism may be a risk factor for glioma development, especially in Asians.
Highlights
Gliomas are the most common central nervous system tumors and account for approximately 80% of primary malignant brain tumors (Schwartzbaum et al, 2006; Jemal et al, 2009)
Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of the association. This meta-analysis showed the X-ray repair crosscomplementing group 3 (XRCC3) Thr241Met polymorphism to be significantly associated with decreased glioma risk in the allelic model (Met allele vs. Thr allele: OR= 0.708, 95%CI= 0.631-0.795)
A number of researches have shown that XRCC3 Thr241Met is a susceptible factor for several cancers, such as lung, breast, colorectal and bladder cancers (Lopez-Cima et al, 2007; Mittal et al, 2012; Romanowicz-Makowska et al, 2012; Zhao et al, 2012), and previous studies have suggested that the XRCC3 Thr241Met polymorphism is suspected with glioma risk
Summary
Gliomas are the most common central nervous system tumors and account for approximately 80% of primary malignant brain tumors (Schwartzbaum et al, 2006; Jemal et al, 2009). The cumulative results are still inconclusive due to various ethnicities, age, histological types and so on We performed this meta-analysis based on all eligible case-control studies in order to investigate the association strength between the XRCC3 Thr241Met polymorphism and glioma risk. Results: This meta-analysis showed the XRCC3 Thr241Met polymorphism to be significantly associated with decreased glioma risk in the allelic model (Met allele vs Thr allele: OR= 0.708, 95%CI= 0.631-0.795). We observed a statistically significant association between the XRCC3 Thr241Met polymorphism and reduced glioma risk in analyses stratified by ethnicity (Asian) and source of controls (hospital based) in the allelic model. Conclusions: Current evidence suggests that the XRCC3 Thr241Met polymorphism may be a risk factor for glioma development, especially in Asians
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
